These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 29338686)

  • 21. Correction to: The GREENH-City interventional research protocol on health in all policies.
    Porcherie M; Vaillant Z; Faure E; Rican S; Simos J; Cantoreggi NL; Heritage Z; Le Gall AR; Cambon L; Diallo TA; Vidales E; Pommier J
    BMC Public Health; 2017 Nov; 17(1):865. PubMed ID: 29110654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials.
    Renda G; di Nicola M; De Caterina R
    Am J Med; 2015 Sep; 128(9):1007-14.e2. PubMed ID: 25910790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Anticoagulation in atrial fibrillation. Strategies in special situations].
    Volkmann H; Walter M; Walter C; Vetter S
    Clin Res Cardiol Suppl; 2011 May; 6():58-65. PubMed ID: 22528179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.
    Nairooz R; Sardar P; Pino M; Aronow WS; Sewani A; Mukherjee D; Paydak H; Maskoun W
    Int J Cardiol; 2015; 187():345-53. PubMed ID: 25839640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overcoming global challenges in stroke prophylaxis in atrial fibrillation: The role of non-vitamin K antagonist oral anticoagulants.
    Massaro A; Giugliano RP; Norrving B; Oto A; Veltkamp R
    Int J Stroke; 2016 Dec; 11(9):950-967. PubMed ID: 27703066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of anticoagulants in elderly patients.
    Bauersachs RM
    Thromb Res; 2012 Feb; 129(2):107-15. PubMed ID: 22014849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Ten questions awaiting for a definitive answer on the use of non-vitamin K oral anticoagulants in atrial fibrillation].
    Cemin R; Di Pasquale G; Colonna P; De Caterina R
    G Ital Cardiol (Rome); 2016 Nov; 17(11):884-896. PubMed ID: 27996992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical trials of new anticoagulants.
    Anderson J; O'Donnell M
    Vnitr Lek; 2006 Mar; 52 Suppl 1():123-6. PubMed ID: 16637460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?
    Dzeshka MS; Lip GY
    Trends Cardiovasc Med; 2015 May; 25(4):315-36. PubMed ID: 25440108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long‑term prevention of thromboembolic complications in patients with atrial fibrillation?
    Riva N; Lip GY
    Pol Arch Med Wewn; 2012; 122(1-2):45-53. PubMed ID: 22353706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antithrombotic prevention in atrial fibrillation: the new anticoagulant drugs].
    Durin O; Donato G; Nanetti M; Foffa A; Inama G
    G Ital Cardiol (Rome); 2012 Oct; 13(10 Suppl 2):16S-20S. PubMed ID: 23096369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apixaban in the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation.
    Pujadas-Mestres L; Escolar G; Arellano-Rodrigo E; Galán AM
    Drugs Today (Barc); 2013 Jul; 49(7):425-36. PubMed ID: 23914351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stroke prevention versus bleeding risk of vitamin-K antagonists: a double-edged sword in patients with atrial fibrillation who require surgery.
    Dobrev D; Goette A; Ravens U
    Cardiovasc Ther; 2009; 27(4):223-5. PubMed ID: 19903184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health status, geriatric syndromes and prescription of oral anticoagulant therapy in elderly medical inpatients with atrial fibrillation.
    Bo M; Sciarrillo I; Maggiani G; Falcone Y; Iacovino M; Grisoglio E; Fonte G; Grosjean S; Gaita F
    Geriatr Gerontol Int; 2017 Mar; 17(3):416-423. PubMed ID: 26818463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Residential medication management reviews of antithrombotic therapy in aged care residents with atrial fibrillation: assessment of stroke and bleeding risk.
    Nishtala PS; Castelino RL; Peterson GM; Hannan PJ; Salahudeen MS
    J Clin Pharm Ther; 2016 Jun; 41(3):279-84. PubMed ID: 27062272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-vitamin K antagonist oral anticoagulants and heart failure.
    Isnard R; Bauer F; Cohen-Solal A; Damy T; Donal E; Galinier M; Hagège A; Jourdain P; Leclercq C; Sabatier R; Trochu JN; Cohen A
    Arch Cardiovasc Dis; 2016 Nov; 109(11):641-650. PubMed ID: 27836786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial.
    De Caterina R; John Camm A
    Europace; 2016 Jan; 18(1):6-11. PubMed ID: 26450845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonvitamin K antagonist oral anticoagulants in everyday practice: Stroke prevention in atrial fibrillation and treatment of venous thromboembolism.
    Bentz BA
    J Am Assoc Nurse Pract; 2015 Dec; 27(12):721-31. PubMed ID: 26676209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vitamin K antagonists. Ready to be replaced?
    Steffel J; Luscher TF
    Hamostaseologie; 2012; 32(4):249-57. PubMed ID: 22955200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.